Friday, April 26, 2024, Washington, DC, 6:00 AM – 7:30 AM Eastern Time

What I Tell My Patients: Integrating New Research Information into Current Clinical Care

A Complimentary NCPD Hybrid Symposium Series Held During the 49th Annual ONS Congress

Head and Neck Cancer

 
Location
Marriott Marquis Washington, DC
901 Massachusetts Avenue NW
Washington, DC 20001
Hotel Phone: (202) 824-9200

Program Schedule — Eastern Time
5:30 AM – 6:00 AM — Registration
6:00 AM – 7:30 AM — NCPD Breakfast Meeting

Meeting Room
Independence Ballroom (Meeting Level 4)

This event will also be webcast live.
Please see Registration tab for details.

There is no registration fee for this event. For the in-person symposium in Washington, DC, preregistration is required as seating is limited.  
 
Faculty
Meetal Dharia, NP-C, AOCNP
Division of Hematology/Oncology
UCLA Health
Los Angeles, California

Robert L Ferris, MD, PhD
Director, UPMC Hillman Cancer Center
Hillman Professor of Oncology
UPMC Senior Vice President for Oncology Programs
Associate Senior Vice Chancellor
for Cancer Research
University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania


Robert Haddad, MD
Chief, Division of Head and Neck Oncology
McGraw Chair in Head and Neck Oncology
Institute Physician
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Lynsey P Teulings, APRN
Nurse Practitioner
Head and Neck Medical Oncology
Smilow Cancer Hospital
at Yale New Haven Health
New Haven, Connecticut

Moderator
Neil Love, MD
Research To Practice
Miami, Florida


Meeting space has been assigned to provide a satellite symposium supported by Coherus BioSciences and EMD Serono Inc during the Oncology Nursing Society’s (ONS) 49th Annual Congress, April 24-28, 2024 in Washington, DC. The Oncology Nursing Society’s assignment of meeting space does not imply product endorsement.
Program Schedule — Eastern Time
5:30 AM – 6:00 AM — Registration
6:00 AM – 7:30 AM — NCPD Breakfast Meeting

What I Tell My Patients About ...

The Biology of Head and Neck Cancer

  • Anatomic locations in which head and neck cancer can occur (eg, larynx/hypopharynx, nasal cavity/paranasal sinus, nasopharynx, oral cavity/oropharynx, salivary gland); implications of primary tumor location for treatment planning
  • Staging of head and neck cancer; significance of disease stage for prognosis and treatment
  • Role of certain viruses, such as the human papillomavirus (HPV) and the Epstein-Barr virus, in head and neck cancer pathogenesis; ramifications of HPV status, if any, for patient outcomes and therapeutic decision-making
  • Other risk factors for the development of head and neck cancer, such as tobacco use, heavy alcohol consumption, environmental or occupational inhalants and radiation exposure

The Multidisciplinary Treatment of Head and Neck Cancer

  • Importance of interdisciplinary coordination in formulating a treatment plan for patients with head and neck cancer
  • Role of various specialists, such as surgeons, radiation oncologists, medical oncologists, nurses, dentists, speech therapists and nutritionists, in the care of patients with head and neck cancer
  • Indications for surgery in head and neck cancer; types of surgical procedures employed for various disease subtypes
  • Rationale for the use of radiation therapy and/or chemotherapy as adjuvant or neoadjuvant treatment for head and neck cancer in patients undergoing surgery or as primary therapy for those with potentially curable disease who are not surgical candidates

The Potential Short- and Long-Term Effects of Surgery for Head and Neck Cancer

  • Educating patients regarding wound care, potential need for feeding or tracheostomy tubes and, if applicable, tracheostomy care
  • Potential for xerostomia, trismus, dysphagia, cranial nerve dysfunction, dental problems and other long-term effects in patients undergoing head and neck cancer surgery; appropriate interventions for each
  • Likelihood of altered dietary intake among patients with head and neck cancer; strategies to address weight loss, dehydration and nutritional deficiencies
  • Counseling patients who are struggling with the cosmetic outcomes of head and neck cancer surgery; role of and coordination with cosmetic surgeons and mental healthcare professionals

Radiation Therapy and Chemotherapy Side Effects

  • Spectrum of adverse effects associated with radiation therapy (eg, fatigue, hearing loss, dysphagia, xerostomia, carotid stenosis, hypothyroidism, strictures, fistula formation, osteoradionecrosis)
  • Potential for common and serious side effects with chemotherapy; appropriate monitoring strategies and patient education regarding when to contact the care team
  • Relative timing of radiation therapy- and chemotherapy-associated toxicities
  • Available supportive management strategies for side effects associated with radiation therapy and chemotherapy

Ongoing Screening and Prevention After Potentially Curative Therapy for Head and Neck Cancer

  • Optimal surveillance and follow-up after potentially curative treatment
  • Counseling applicable patients who have undergone treatment for head and neck cancer about the importance of tobacco and alcohol cessation
  • Other post-treatment lifestyle recommendations, including those on diet, exercise and sun safety
  • Educating patients on possible signs and symptoms of recurrence, such as a new mass, unexplained weight loss, fatigue or pain

Emerging Treatment Strategies Aimed at Improving Outcomes Associated with Localized or Locally Advanced Head and Neck Cancer

  • Long-term outcomes observed with the traditional treatment paradigm for localized or locally advanced head and neck cancer; proportion of patients with locally advanced disease who develop locoregional recurrence or distant metastases
  • Educating patients regarding the potential advantages of participating in a clinical research study of a novel investigational strategy
  • Scientific justification for targeting inhibitors of apoptosis proteins for locally advanced squamous cell carcinoma of the head and neck (SCCHN); mechanism of action of xevinapant
  • Reductions in the risk of locoregional recurrence, disease progression and death observed with the addition of xevinapant to chemoradiation therapy among patients with locally advanced SCCHN in early clinical trials
  • Ongoing and planned Phase III studies of xevinapant for locally advanced SCCHN; estimated completion dates

Tolerability Considerations with Xevinapant

  • Common patient misperceptions regarding the safety of clinical trial participation and strategies to dispel these concerns
  • Preparing interested patients with head and neck cancer for trial participation; instructions regarding adherence, monitoring requirements, adverse event (AE) reporting, et cetera
  • Proportion of patients experiencing late-onset toxicities with xevinapant in combination with chemoradiation therapy versus chemoradiation therapy alone in published clinical trials
  • Most common late-onset toxicities, such as dry mouth, dysgeusia, dysphagia and fibrosis, reported with xevinapant in combination with chemoradiation therapy

The Established Role of Anti-PD-1/PD-L1 Antibodies in Therapy for Advanced Head and Neck Cancer

  • Rationale for the activity of immune checkpoint inhibitors in head and neck cancer
  • Principal findings with pembrolizumab as monotherapy or in combination with platinum/5-FU as first-line treatment for recurrent or metastatic SCCHN
  • Indications for pembrolizumab monotherapy and pembrolizumab/chemotherapy for recurrent or metastatic SCCHN; impact of PD-L1 status and other factors on patient selection for these regimens
  • Clinical trial database supporting the use of pembrolizumab and nivolumab for patients with relapsed metastatic SCCHN

Newly Approved Immunotherapeutic Strategies for Nasopharyngeal Carcinoma

  • Unique histopathology, etiology, clinical behavior and natural history of nasopharyngeal carcinoma relative to other squamous cell carcinomas of the head and neck
  • Similarities and differences between toripalimab and other anti-PD-1/PD-L1 antibodies
  • Efficacy and safety findings reported with toripalimab in combination with platinum-based chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma
  • Key outcomes documented with toripalimab as monotherapy in the second-line setting and beyond
  • Recent FDA approval of toripalimab in nasopharyngeal carcinoma and current clinical role

The Tolerability of Immune Checkpoint Inhibitors

  • Pathophysiology, incidence and spectrum of immune-mediated and other AEs observed with anti-PD-1/PD-L1 antibodies
  • Impact on the tolerability of anti-PD-1/PD-L1 antibodies when administered in combination with chemotherapy
  • Optimal monitoring and management of immune-related and other AEs with anti-PD-1/PD-L1 antibodies
  • Relative and absolute contraindications to the use of immune checkpoint inhibitor therapy; role, if any, for patients with preexisting autoimmune complications

Target Audience
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of head and neck cancer.

Learning Objectives
Upon completion of this activity, participants should be able to

  • Appreciate the importance of interdisciplinary coordination when formulating a treatment plan for head and neck cancer, and recognize the roles that various specialists play in long-term patient care.
  • Develop a plan to manage the short- and long-term adverse effects associated with multimodal management of localized and locally advanced head and neck cancer to support patient quality of life and continuation of treatment.
  • Recall long-term outcomes with traditional treatment approaches for localized or locally advanced head and neck cancer, and assess clinical, biological and patient-specific factors that increase the risk of recurrence after primary therapy.
  • Evaluate research findings with novel agents targeting inhibitors of apoptosis proteins in patients with locally advanced squamous cell carcinoma of the head and neck, and contemplate the potential role of this approach in clinical management.
  • Appraise clinical trial data documenting the efficacy and safety of immune checkpoint inhibitors in various recurrent or metastatic head and neck cancer subtypes, and consider the current utility of these agents for newly diagnosed and progressive disease.
  • Recall the design of ongoing clinical trials evaluating novel agents and strategies for head and neck cancer, and counsel appropriate patients about availability and participation.

Accreditation Statement
Research To Practice is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

Credit Designation Statements
This educational activity for 1.5 contact hours is provided by Research To Practice.

This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.

ONCC/ILNA Certification
This program will be submitted for ONCC/ILNA certification.

Credit Form
To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form. A credit form link will be given to each participant as part of the meeting course materials.

Unlabeled/Unapproved Uses Notice
There is no implied or real endorsement of any product by RTP or the ANCC.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTYMs Dharia and Dr Haddad have no relevant conflicts of interest to disclose. The following faculty reported relevant financial relationships with ineligible entities:

Dr FerrisAdvisory Boards: Adaptimmune, Bristol Myers Squibb, Coherus BioSciences, CureVac, CytoAgents, Eisai Inc, Genmab US Inc, Hookipa Pharma Inc, Instil Bio, Lifescience Dynamics, MacroGenics Inc, MeiraGTx, Merck, Merus, Numab Therapeutics AG, Oncocyte, Pfizer Inc, Rakuten Medical Inc, Regeneron Pharmaceuticals Inc, Seagen Inc, SIRPant Immunotherapeutics Inc, Vir Biotechnology Inc; Clinical Trial, Research Funding: Bristol Myers Squibb. Ms TeulingsAdvisory Committee: EMD Serono Inc.

MODERATORDr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME/NCPD activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI Biopharma, a Sobi company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Legend Biotech, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.

RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from Coherus BioSciences and EMD Serono Inc.

Marriott Marquis Washington, DC
901 Massachusetts Avenue NW
Washington, DC 20001
Hotel Phone: (202) 824-9200

Meeting Room:
Independence Ballroom (Meeting Level 4)

The Marriott Marquis Washington, DC is the headquarters hotel for the 2024 ONS Congress and is connected to the Walter E Washington Convention Center by an underground concourse.

 

This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of head and neck cancer.

There is no registration fee for this event. For the in-person symposium in Washington, DC, preregistration is required as seating is limited.

NOTICE:
Registration for this event is independent of registration for the 2024 ONS Congress.

IN-PERSON Registration for nurses and other healthcare providers

I am a practicing nurse or other healthcare provider involved in the treatment of cancer.

IN-PERSON Registration
for clinicians »
IN-PERSON Registration for other/industry professionals*

Please note, a limited number of seats are available to other/industry professionals on a first come, first served basis.

IN-PERSON Registration
for nonclinicians »
* Individuals employed by for-profit organizations, including financial institutions, biotech or pharmaceutical companies
LIVE WEBCAST Registration for all professionals

Please note we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions.

REGISTRATION FOR WEBCAST »
Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk at least 15 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.